Abbott's HUMIRA Study Meets Primary Endpoints

The study analysis included 494 adult patients with UC who had not responded well to conventional therapy.

Abbott's HUMIRA? (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis.

Ulcerative colitis (UC) is a chronic autoimmune disease that causes inflammation and ulceration in the lining of the colon or large intestine. It is estimated that approximately 700,000 people in the United States have UC. Symptoms include abdominal cramping, rectal bleeding, increased bowel movements and diarrhea.

"There is an unmet need for patients living with ulcerative colitis," said William J. Sandborn, M.D., division chief, Gastroenterology, University of California, San Diego and primary investigator for the study. "Unmanaged disease lends itself to painful symptom flares that can negatively impac